Defects in the annulus fibrosus (AF) of intervertebral discs allow nucleus pulposus tissue to herniate causing painful disability. Microdiscectomy procedures remove herniated tissue fragments but unrepaired defects remain allowing reherniation or progressive degeneration. Cell therapies show promise to enhance repair but methods are undeveloped and carriers are required to prevent cell leakage. To address this challenge, this study developed and evaluated genipin-crosslinked fibrin (FibGen) as an adhesive cell carrier optimized for AF repair that can deliver cells, match AF material properties and have low risk of extrusion during loading. Part 1 determined feasibility of bovine AF cells encapsulated in high concentration FibGen (F140G6: 140mg/ml fibrinogen; 6mg/ml genipin) for 7 weeks could maintain high viability, but had little proliferation or matrix deposition. Part 2 screened tissue mechanics and in situ failure testing of nine FibGen formulations (fibrin: 35-140mg/ml; genipin: 1-6 mg/ml). F140G6 formulation matched AF shear and compressive properties and significantly improved failure strength in situ.
Introduction
Back pain is a chronic condition that significantly impacts quality of life and affects up to one billion people worldwide (1, 2) . Back pain severity and disability is strongly correlated with herniation, severe intervertebral disc (IVD) degeneration or the presence of prominent modic changes (3) (4) (5) (6) . Conservative care for IVD disorders include pain medication, spinal injections, and physical therapy, yet these treatments often have limited efficacy (7, 8) . Microdiscectomy, in which herniated tissue is removed, is the most common procedure performed after conservative care has failed for mechanical back pain and leg pain with herniation with strong symptomatic improvement compared to conservative treatment (9) (10) (11) . However these procedures do not repair annulus fibrosus (AF) defects created by herniation and subsequent microdiscectomy, and 10-30% of patients experience reherniation, degeneration and/or recurrent pain at the operative level (12, 13) . We believe that biomaterials that match IVD material properties and seal AF defects may help inhibit back pain by preventing reherniation and restoring IVD biomechanical behaviors to the healthy condition.
Clinical trials utilizing cellular therapies for reducing pain from IVD degeneration show promise, and it is speculated that efficacy is due to the new cells modulating inflammation or promoting repair (14, 15) . However, implantation of cells is challenging due to poor cell survival, cell leakage, and potential for unwanted off-target effects such as osteophyte formation (16) (17) (18) (19) (20) . The optimal cell type for AF repair has not been established yet, although some clinical improvement has been observed for human clinical trials utilizing bone marrow-derived mesenchymal stem cells (MSCs) (21, 22) , juvenile articular chondrocytes (23) and IVD cells (24, 25) . The largest clinical trials thus far have used autologous IVD cells. IVD cell injections reduced symptoms of low back pain and prevented IVD height loss, and suggested that development of carriers that might imbue additional potential or scaffolds that enhance placement as a basis for treatment should remain the next considerations (24) .
Several biomaterials for IVD repair have been developed (26) (27) (28) . Using a cell carrier biomaterial may address the challenges for IVD cell delivery, by improving cell survival, preventing cell leakage and providing a supportive scaffold for cellular growth and activity.
An ideal cell carrier for AF repair would be injectable and allow easy translation to current This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. surgical procedures, would seal irregularly-shaped IVD defects to prevent or slow chemical degeneration, would restore IVD height and biomechanical behaviors, would withstand the challenging physiological mechanical loading environment of the IVD without reherniation, and would degrade slowly to enable healing to occur (27, 29, 30 ).
There is an unmet need to develop a biomaterial that can fulfill mechanical demands required for AF repair while enabling cell proliferation and matrix production. Fibrin crosslinked with genipin (FibGen) fulfills many of the required mechanical roles of a cell carrier for AF repair since it is injectable, fills irregularly shaped defects, rapidly gels for easy clinical translation, can be mechanically tuned to match native AF shear properties, and partially restores IVD biomechanical behaviors following injury with little herniation risk (31-34). While high genipin concentrations can prevent cell growth or induce cell death (35-37), there is some evidence that fibrin with low genipin concentrations can promote cell survival and matrix production (34). The objectives of this study were to develop FibGen as a cell-seeded AF repair sealant and to determine optimal fibrin and genipin concentrations that meet mechanical design requirements for AF repair while also promoting cell survival and extracellular matrix production.
Materials and Methods

Study Design
The three-part study design included the following. Part 1 determined the feasibility of using FibGen with high fibrin and genipin concentrations as a cell seeded hydrogel by performing a 49-day 3D cell culture study that assessed bovine AF cell viability and proliferation, glycosaminoglycan (GAG) production, and hydrogel biomechanical properties (Fig. 1) . Part 2 screened nine distinct FibGen acellular hydrogel formulations to identify the lowest fibrin and genipin concentrations that would match AF tissue material properties in unconfined compression and shear. Four formulations were chosen for additional in situ failure testing to identify the failure strength when hydrogel failure occurred. These acellular formulations were analyzed immediately following gelation. Part 3 screened biological performance of bovine AF cells encapsulated in 4 formulations of FibGen in a 7-day 3D cell culture experiment with assessments of cell viability, proliferation, Collagen I production, and glycosaminoglycan (GAG) content. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
Hydrogel Fabrication
FibGen formulations were mixed using a dual barrel syringe with mixing tip (4:1 syringe, Pacific Dental, Walnut, California, USA). Fibrinogen dissolved in phosphate buffered saline (PBS) and mixed thoroughly with low glucose DMEM (Fisher Scientific, Pennsylvania, USA) with or without cells was pipetted into the large syringe barrel and thrombin, genipin (dissolved in DMSO) and serum-free DMEM was pipetted into the small barrel. After mixing, FibGen was injected into a 5x5mm cylindrical mold and cured for 4 hours at 37°C. Formulations of fibrinogen and genipin denote final concentrations of each component (Table 1) . FibGen concentrations were selected to include 140 mg/mL of fibrinogen and 6 mg/mL of genpin which was previously optimized and analyzed for mechanical performance (32,35), as well as a wide range of FibGen concentrations with reduced fibrin and genipin concentration to screen for improved biological and mechanical performance for cell delivery. The formulations presented in this study are not clinically approved for use in humans.
Cell Isolation and Expansion
Bovine AF cells were obtained by primary isolation from skeletally mature bovine IVDs (n=4) obtained from a local abattoir (Green Village Packing Co., Green Village, NJ This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
(Napco Series 8000 WJ, Thermo Scientific, Pennsylvania, USA). 
Cell Viability and Proliferation
Cell viability and proliferation were assessed using confocal microscopy on calcein AM/DAPI dual-stained FibGen gels that were cut in half to visualize the middle of the gel. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
nucleus were considered immunonegative, cells with chromogen present in the nucleus and cytoplasm or nucleus alone were considered immunopositive.
Immunohistochemistry (IHC)
Chromogenic IHC was performed to assess Collagen I (COL1) production and cellular proliferation (Ki67) after 1 week of culture (Part 3 of this study). Day 7 cell-laden FibGen samples were fixed in aqueous buffered zinc formalin fixative (Anatech Ltd., Battle
Creek MI). After fixation and processing, samples were embedded in paraffin wax using Leica HistoCore Arcadia H and C. Blocks were then sectioned using a Leica RM 2165 Rotary
Microtome to produce 5µm thick sections mounted on Millennia 1000 Adhesion Slides No. 12-544-14; Fisher Scientific, Fair Lawn NJ) were applied to slides. All samples were imaged using bright-field microscopy on the Zeiss AxioImager Z1 (Carl Zeiss Microscopy GmbH, Jena Germany).
To assess the validity of the immunostaining patterns, antigen/positive tissue controls and reagent controls were incorporated. For anti-Collagen 1, the mouse intervertebral disc was included alongside experimental samples (outer AF structure). For anti-Ki67, the mouse small intestine was included alongside experimental samples (Crypts of Lieberkühn). Reagent control conditions for experimental and positive tissue control samples involved a secondary antibody-only application to ensure antigen detection was strictly due to the primary antibody.
Matrix Production
Visual assessment of pericellular matrix production was performed using scanning electron microscopy (SEM). FibGen gels (n=3) were fixed in 3% gluteraldehyde, followed by 1% Osmium Tetroxide and then dehydrated in ethyl alcohol and embedded in Embed 812 This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
for TEM (H760 TEM Hitachi High Technologies, Northridge, CA) or dried and gold sputtered for SEM (5kV, S4300 SEM Hitachi High Technologies).
Quantitative assessment of GAG content produced by cells over time was performed using Blyscan Assay (UK Biocolor, Carrickfergus, UK) on FibGen digests according to the manufacturer's protocol.
A semi-quantitative analysis was completed on the Collagen 1 immunostained samples to determine if there were any significant differences in Collagen 1 production when screening FibGen formulations. Manual cell counting of immunostained samples was completed as follows: cells without any chromogen presence in the pericellular space were considered immunonegative and cells with chromogen present in the pericellular space were considered immunopositive.
Biomechanics and Formulation Screening
Biomechanical and degradation properties of FibGen F140G6 hydrogels from Part 1
were assessed by measuring dry weight at each time point and normalizing to day 1 values of dry weight. Young's compressive modulus was calculated from unconfined compression testing at a 0.2% strain/sec rate using the initial 20% strain (ELF 3200 TA Instruments, New
Castle, DE, USA). Complex shear modulus (|G*|, 0.5Hz) was measured using a frequency sweep (0.05 to 5 Hz at 1% strain) on a parallel plate rheometer on 5mm diameter and 5mm height gels (AR2000ex, TA Instruments, New Castle, DE). Sample size n=4 was used for biomechanical measurements in Part 1 and Part 2 studies.
In Situ Failure Testing
Bovine caudal IVD motion segments were isolated and ligaments and tendons were removed to expose the AF. All IVDs were frozen at -20°C until use. The motion segments (n=9/formulation group) underwent two parallel cuts (IsoMet 1000, Buehler, Lake Bluff, IL) 3mm away from each endplate and then thawed at 37°C for 2 hours. A 4mm biopsy punch was used to create an injury on the left posterolateral side of the IVD and the nucleus was disrupted with a curette for 1 min before 90-120mg of NP tissue was removed with a rongeur. Repaired groups were filled with F140G6, F140G1, or F70G1 FibGen formulation shortly after injury. All groups were submerged in PBS overnight at 37°C before mechanical 
Results
Feasibility of FibGen as a Cell Carrier
Bovine AF cells seeded within FibGen had high viability above 85% with no significant change through Day 49 (p>0.69), but notably had no increase in cell number (p=0.78) (Fig.   2 ). These seeded bovine AF cells produced extracellular matrix that was localized to pericellular regions within FibGen as observed by SEM (Fig. 3) . However GAG production was not significantly increased as measured by Blyscan (p=0.74). Dry weight and compressive modulus of both cell-seeded and acellular gels remained stable for up to 49 days with no effect of cell-seeding (p>0.17) (Fig. 4) . This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
FibGen Formulation Screening
Compression and shear testing demonstrated that the biomechanical properties of fibrin concentration from 140mg/mL to 70mg/mL had no effect for a given genipin concentration, but using 35mg/mL of fibrin decreased the compressive modulus when using 6 or 2 mg/mL of genipin (p<0.0033). For shear modulus, decreasing fibrin concentration at a given genipin concentration significantly reduced modulus values (p<0.0029) (Fig. 5B) .
In Situ Failure Testing
The four candidate FibGen formulations were easily injected into large IVD defects.
Greater attention was required when handling high macromer and crosslinking formulations to ensure that no bubbles formed within the hydrogels. All intact samples failed via endplate fracture which was identified as a drop in the stress-displacement curve with no visual sign of herniation (Fig. 6A ). Injured and repair samples failed via herniation of NP tissue which was confirmed visually and with a corresponding abrupt drop in the stress-displacement curve (Fig. 6B ). Failure strength (Fig. 6C ) and subsidence to failure (Fig.   6D ) for all injured and FibGen repaired samples were significantly lower than intact samples (p<0.0001). F140G6 significantly improved those parameters compared to the injured group (p=0.0343).
Biological Screening of FibGen Formulations
Bovine AF cells were seeded in four FibGen formulations for 7 days and were assessed for viability, proliferation, Collagen 1 production, and GAG content. Viability increased as FibGen concentration decreased, with viability of cells in F35G1 significantly greater than viability within F140G6 (p=0.014) (Fig. 7A,C This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
than F140G6 at Day 1 (p=0.014) (Fig. 7D) . However, no groups displayed an increase of cells within this timeframe. DNA quantification displayed similar trends where F70G1 and F35G1 had significantly greater DNA than F140G6 at Day 1 (p<0.0469). DNA in F35G1 was also significantly greater than F140G1 at Day 1 (p=0.0047) (Fig. 7E) . Day 7 DNA quantification data agreed with semi-quantitative Ki67 IHC data, as no significant differences were found in Ki67 immunopositivity across all screened FibGen formulations (p>0.3) (Fig. 7B) . Semi-quantitative analysis of Collagen 1 IHC (Fig. 8A) This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
production surrounding a cell could be seen in the day 49 SEM images, but GAG quantification with Blyscan assay indicated no significant changes over time. AF cells mainly produce collagens and it is possible that the matrix observed in SEM images consisted mainly of collagen, which was not measured in this part of the study, and it was apparent that extracellular matrix production was limited.
Biomechanical performance of F140G6 FibGen gels was excellent and showed no significant changes in compressive modulus over time or between acellular and cellseeded hydrogels. The lack of substantial matrix production in F140G6 may have been due to the high concentration of macromolecules surrounding the cell, as seen in the day 1 SEM images, which limited cell motility, proliferation and matrix production for the duration of the 49 day experiment. Genipin crosslinking provided a stable and stiff hydrogel, which might account for the limited biological cell activity once embedded. It is notable that the mechanics of this FibGen formulation were stable with time also confirming that little degradation occurred.
The lack of proliferation or significant extracellular matrix production in F140G6 gels This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
of fibrin used in our studies on AF repair are substantially greater than fibrin-based biomaterials for most other purposes (46) . There were more cells/mm 2 in the 1mg/mL genipin concentration formulations than F140G6 which suggests some genipin cytotoxicity during gel creation.
This three-part study has some limitations requiring further investigation prior to translation to humans. IVD cells and MSCs are both commonly used for IVD repair (14) .
This study selected bovine AF cells for seeding since they are readily available, are Multiple AF repair biomaterials are available with demonstrated capacity to fill voids from AF defects and restore IVD volume, and in some cases they can also restore biomechanical properties of the motion segment and produce extracellular matrix (26, (54) (55) (56) (57) (58) (59) . Biological performance of some AF repair biomaterials surpasses the cell-seeded
FibGen described in the present study. However, many of these biomaterials with strong biological performance have failure behaviors that have not been evaluated and are expected to be poor due to relatively low moduli values. We apply a screening methodology in this study that most strongly focused on biomechanical performance and reherniation risk (29) in order to prioritize safety and reduce need for a potential surgical revision procedure. Cell delivery with AF biomaterials or NP replacement biomaterials with This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
greater biological performance and inferior biomechanical performance can be considered (27, 28, 30) particularly if augmented with an AF closure device that helps to reduce reherniation risk (60) . Repair biomaterials or patches that mimic the AF fibrillar structure can also better match tensile properties of the AF (61, 62) , yet adhesion and integration with native tissues remain a challenge. The appeal of enhancing cell-seeded FibGen performance is that it is an adhesive, void-filling biomaterial that can be delivered in a simple single injection procedure and has low herniation risk.
We conclude that FibGen is a tunable AF sealant with potential for cell-delivery to promote AF repair after microdiscectomy procedures or during intradiscal injection procedures. This study screened 9 FibGen formulations to arrive at two formulations deserving additional investigation. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof. This paper has been peer-reviewed and accepted for publication, but has yet to undergo copyediting and proof correction. The final published version may differ from this proof.
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